INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics
GET POWR RATINGS... FREE!
INMB POWR Grades
- Momentum is the dimension where INMB ranks best; there it ranks ahead of 39.4% of US stocks.
- INMB's strongest trending metric is Stability; it's been moving down over the last 52 weeks.
- INMB ranks lowest in Stability; there it ranks in the 2nd percentile.
INMB Stock Summary
- INMB's price/sales ratio is 8,980.37; that's higher than the P/S ratio of 99.71% of US stocks.
- With a year-over-year growth in debt of 9,203.19%, Inmune Bio Inc's debt growth rate surpasses 99.69% of about US stocks.
- Revenue growth over the past 12 months for Inmune Bio Inc comes in at 128.25%, a number that bests 94.3% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Inmune Bio Inc, a group of peers worth examining would be MRSN, KROS, URG, ZOM, and BNTC.
- Visit INMB's SEC page to see the company's official filings. To visit the company's web site, go to www.inmunebio.com.
INMB Valuation Summary
- INMB's price/earnings ratio is -21.9; this is 160% lower than that of the median Healthcare stock.
- Over the past 31 months, INMB's price/sales ratio has gone NA NA.
- INMB's price/sales ratio has moved NA NA over the prior 31 months.
Below are key valuation metrics over time for INMB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| INMB | 2021-08-31 | 38172.7 | 9.7 | -21.9 | -20.6 |
| INMB | 2021-08-30 | 36372.7 | 9.3 | -20.9 | -19.6 |
| INMB | 2021-08-27 | 32236.4 | 8.2 | -18.5 | -17.2 |
| INMB | 2021-08-26 | 31027.3 | 7.9 | -17.8 | -16.5 |
| INMB | 2021-08-25 | 30227.3 | 7.7 | -17.4 | -16.1 |
| INMB | 2021-08-24 | 31527.3 | 8.0 | -18.1 | -16.8 |
INMB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- INMB has a Quality Grade of D, ranking ahead of 11.03% of graded US stocks.
- INMB's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows INMB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | 1 | -3.952 |
| 2021-03-31 | 0 | 1 | -15.163 |
| 2020-12-31 | 0 | 1 | -22.264 |
| 2020-09-30 | 0 | NA | -21.947 |
| 2020-06-30 | 0 | NA | -15.048 |
| 2020-03-31 | 0 | NA | -9.777 |
INMB Price Target
For more insight on analysts targets of INMB, see our INMB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.75 | Average Broker Recommendation | 1.38 (Strong Buy) |
INMB Stock Price Chart Interactive Chart >
INMB Price/Volume Stats
| Current price | $12.72 | 52-week high | $30.37 |
| Prev. close | $12.54 | 52-week low | $8.40 |
| Day low | $12.40 | Volume | 20,082 |
| Day high | $12.99 | Avg. volume | 345,151 |
| 50-day MA | $17.24 | Dividend yield | N/A |
| 200-day MA | $16.31 | Market Cap | 226.96M |
INmune Bio Inc. - Common stock (INMB) Company Bio
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Latest INMB News From Around the Web
Below are the latest news stories about Inmune Bio Inc that investors may wish to consider to help them evaluate INMB as an investment opportunity.
CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of DirectorsDURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors. “As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy,” stated Dr. Charles Nicolette, chief exec |
INmune Bio (NASDAQ:INMB) Downgraded by Zacks Investment ResearchZacks Investment Research cut shares of INmune Bio (NASDAQ:INMB) from a hold rating to a sell rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The companys product platform consists of [] |
How Much Of INmune Bio, Inc. (NASDAQ:INMB) Do Insiders Own?If you want to know who really controls INmune Bio, Inc. ( NASDAQ:INMB ), then you'll have to look at the makeup of its... |
Zacks: Brokerages Anticipate INmune Bio, Inc. (NASDAQ:INMB) Will Announce Earnings of -$0.55 Per ShareEquities analysts forecast that INmune Bio, Inc. (NASDAQ:INMB) will post earnings per share (EPS) of ($0.55) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for INmune Bios earnings. INmune Bio reported earnings per share of ($0.24) in the same quarter last year, which suggests a negative year-over-year growth rate [] |
INmune Bio, Inc. (INMB) CEO R. J. Tesi on Q3 2021 Results - Earnings Call TranscriptINmune Bio, Inc. (INMB) Q3 2021 Earnings Conference Call November 3, 2021 16:30 ET Company Participants David Moss - Co-Founder and Chief Financial Officer R. J. Tesi - Chief Executive Officer and Co-Founder Mark Lowdell - Chief Scientific Officer and Co-Founder C. J. Barnum - Head, Neuroscience Conference Call Participants... |
INMB Price Returns
| 1-mo | -30.83% |
| 3-mo | -46.71% |
| 6-mo | -4.86% |
| 1-year | 43.24% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -26.13% |
| 2020 | 196.90% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...